Zacks Investment Research
18 Jun 2026, 14:55 UTC · 1h ago
ANGO Gains FDA IDE Approval for NanoKnife BPH Feasibility Study
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
18 Jun 2026, 14:55 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The FDA approved AngioDynamics' (ANGO) IDE application to begin the RELIEF study evaluating the NanoKnife System for benign prostatic hyperplasia (BPH). — This expands the addressable market for the NanoKnife technology from oncology to a patient population of approximately 15 million men in the US.
+0.40AngioDynamics shares fell 3.4% following the announcement of the FDA IDE approval. — The immediate market reaction was negative, suggesting investors may have priced in the news or are skeptical of the study's timeline/outcome.
-0.20Which stocks this story touches
FDA approval of an IDE application for the RELIEF study expands the clinical development pathway and potential addressable market for its NanoKnife System.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
11h ago
